Testing three arthritis drugs in healthy volunteers
Treatments studied
This trial tests three arthritis medications in healthy people to understand how safe they are and how the body processes them. It may help in developing future treatments for conditions like rheumatoid arthritis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 32 on the body mass index (BMI) scale.
- You are in generally good health, with no major medical conditions.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You have not had shingles (herpes zoster) more than once, or a severe case of shingles or cold sores.
- You have no history of cancer (except certain easily treated skin cancers).
- You have no active or past tuberculosis (TB) infection.
- You have not taken any of the study drugs (upadacitinib, tofacitinib, baricitinib) in the last 90 days.
- You are not taking any prescription or over-the-counter medications, vitamins, or herbal supplements regularly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody drug (FB1003) for people with knee osteoarthritis pain. It will check if the drug is safe and helps reduce pain. You may be eligible if you have moderate to severe knee pain and are willing to temporarily stop your usual pain medications.
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't improved after trying multiple treatments. It aims to see if the drug can reduce joint pain and swelling when other medications have failed.
Hear when a new Healthy Volunteers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.